Study: Abbott, Edwards may have mislabeled hundreds of patient deaths

By

Abbott (NYSE:ABT) and Edwards Lifesciences (NYSE:EW) may have mislabeled patient deaths as injuries or device malfunctions in hundreds of FDA adverse event reports involving their transcatheter aortic or mitral valve replacement devices, according to a new study.

The study by JAMA Internal Medicine editor Dr. Rita Redberg, former FDA unique device identification (UDI) external program manager Madris Tomes and others examined a total of 10,558 adverse event reports related to Abbott’s MitraClip or Edwards’ Sapien 3 devices from the time the FDA approved them through December 2018.If you want to read more about this news, click here.

Posted in News.
Share

Deja una respuesta

Tu dirección de correo electrónico no será publicada.

Related Posts

  •
    18 junio, 2019

    Stroke significantly increases the risk of dementia

    In the largest study of its kind, researchers conclude that stroke doubles the risk that an individual will eventually develop dementia. If you want to read more about this news click here.

  •
    10 octubre, 2019

    ‘Electronic tongues’ may help diagnose early stage bladder cancer

    New research presents a complex electronic device as a possible new, efficient, simple, and cost-effective way of detecting bladder cancer in its early stages and monitoring people living with bladder cancer. In a quest to find a better way of diagnosing bladder cancer, Spain-based researchers from the Polytechnic University of Valencia (UPV), the La Fe …

  •
    21 febrero, 2020

    COFEPRIS Challenges 2020

    Since December 1st, 2018 a historical change in administration that consisted of a new president who is committed to Public Office cleansing of corrupt and unequal practices had a strong impact on the whole country course of operation. Many institutions were eliminated or were audited and restructured.  Cofepris was audited and analyzed for permanence or …

  •
    18 junio, 2019

    More than 1 million Class I medical device units recalled in Q1

    For the third consecutive quarter, more than one million Class I units were recalled during 2019’s Q1. If you want to read more about this news click here. If you want to read more about this news click here.